Cytosorbents (NASDAQ:CTSO) Receives New Coverage from Analysts at StockNews.com

Equities researchers at StockNews.com began coverage on shares of Cytosorbents (NASDAQ:CTSO) in a research note issued to investors on Thursday. The firm set a “hold” rating on the medical research company’s stock.

Several other research analysts have also commented on the company. HC Wainwright reissued a “neutral” rating and set a $1.00 price objective on shares of Cytosorbents in a report on Wednesday, August 14th. EF Hutton Acquisition Co. I raised Cytosorbents to a “strong-buy” rating in a research note on Monday, July 29th.

Cytosorbents Stock Performance

Cytosorbents stock opened at $1.12 on Thursday. Cytosorbents has a 1-year low of $0.70 and a 1-year high of $2.15. The company has a current ratio of 2.12, a quick ratio of 1.71 and a debt-to-equity ratio of 0.82. The firm has a market capitalization of $60.82 million, a PE ratio of -1.90 and a beta of 0.51. The firm’s 50 day simple moving average is $1.14 and its 200 day simple moving average is $1.00.

Cytosorbents (NASDAQ:CTSO) last released its quarterly earnings results on Tuesday, August 13th. The medical research company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.01. The firm had revenue of $9.89 million for the quarter, compared to analysts’ expectations of $9.73 million. Cytosorbents had a negative net margin of 68.70% and a negative return on equity of 131.84%. During the same quarter in the prior year, the firm posted ($0.14) earnings per share. As a group, analysts expect that Cytosorbents will post -0.32 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Cytosorbents

A number of large investors have recently added to or reduced their stakes in the business. Key Client Fiduciary Advisors LLC raised its stake in shares of Cytosorbents by 188.0% during the first quarter. Key Client Fiduciary Advisors LLC now owns 34,557 shares of the medical research company’s stock valued at $33,000 after acquiring an additional 22,557 shares during the last quarter. Atomi Financial Group Inc. purchased a new position in shares of Cytosorbents during the third quarter valued at approximately $51,000. CM Management LLC raised its stake in Cytosorbents by 3.0% during the second quarter. CM Management LLC now owns 850,000 shares of the medical research company’s stock valued at $598,000 after buying an additional 25,000 shares during the last quarter. Sargent Investment Group LLC boosted its stake in Cytosorbents by 4.9% in the 2nd quarter. Sargent Investment Group LLC now owns 1,433,500 shares of the medical research company’s stock worth $1,008,000 after purchasing an additional 67,181 shares in the last quarter. Finally, Avenir Corp lifted its stake in shares of Cytosorbents by 4.0% in the first quarter. Avenir Corp now owns 3,172,696 shares of the medical research company’s stock worth $3,014,000 after buying an additional 121,294 shares in the last quarter. Hedge funds and other institutional investors own 32.87% of the company’s stock.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.